A Phase 2 Study of Pembrolizumab (MK-3475), DPX-Survivac Vaccine and Low Dose of Cyclophosphamide Combination in Patients With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Trial Profile

A Phase 2 Study of Pembrolizumab (MK-3475), DPX-Survivac Vaccine and Low Dose of Cyclophosphamide Combination in Patients With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Cyclophosphamide (Primary) ; EMD 640744 (Primary) ; Pembrolizumab (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Nov 2017 According to an Immunovaccine media release, early data from this trial are expected in 1H 2018.
    • 11 Apr 2017 According to an Immunovaccine media release, University Health Network's Princess Margaret Cancer Centre (PM) has received Health Canada clearance to initiate this clinical study.
    • 06 Feb 2017 According to an Immunovaccine media release, company expects to initiate enrolment after completion of the contract between Immunovaccine and UHN and pending regulatory clearance from Health Canada.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top